Official Title
Analysis of Screen-detected Lung Cancers' Genomic Traits
Brief Title
Analysis of Screen-detected Lung Cancers' Genomic Traits
Protocol ID
NCT04204499
Lead Sponsor
University College, London
Brief Summary
Prospective, observational cohort study of patients undergoing surgical resection for low
dose CT (LDCT) screen-detected lung cancer (detected through the SUMMIT study-
ClinicalTrials.gov Identifier: NCT03934866/ lung screening programmes), in which
translational research is a fundamental aspect.
Detailed Description
The ASCENT study seeks to examine the genomic signatures of screen-detected cancers, in
order to categorise the biological behaviour of such lesions and correlate this against
non-invasive biological and radiological parameters. From these data, the plan is to
explore strategies to characterise LDCT-detected cancers through non-invasive means,
which the researchers believe may prove key in mitigating potential screening-associated
harms.
Study Period
-
Enrollment Count
526 participants
Eligibility Criteria
Inclusion Criteria:
1. Diagnosed with confirmed lung cancer or probable lung cancer via LDCT screening.
2. Planned for, or completed primary surgical resection either for histologically
confirmed lung cancer, or strongly suspected lung cancer.
3. Able to provide written informed consent (or verbal informed consent for
participants consenting to retrospective diagnostic samples and data collection
only).
Exclusion Criteria:
1. Treatment with neoadjuvant therapy for current lung malignancy as per local MDT
treatment decision.
2. Known Active Human Immunodeficiency Virus (HIV), Hepatitis B virus, Hepatitis C
Virus or Syphilis.
Filters
Lung Cancer
RECRUITING
ADULT
OLDER_ADULT